Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors.

about

Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors.

Item

http://www.wikidata.org/entity/Q47870337

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Second-line treatment persiste ...... utaneous TNF-alpha inhibitors.

@en

Second-line treatment persiste ...... utaneous TNF-alpha inhibitors.

@nl

type

Item

label

Second-line treatment persiste ...... utaneous TNF-alpha inhibitors.

@en

Second-line treatment persiste ...... utaneous TNF-alpha inhibitors.

@nl

prefLabel

Second-line treatment persiste ...... utaneous TNF-alpha inhibitors.

@en

Second-line treatment persiste ...... utaneous TNF-alpha inhibitors.

@nl

P1476

Second-line treatment persiste ...... cutaneous TNF-alpha inhibitors

@en

P2093

Axel Svedbom

http://www.w3.org/2001/XMLSchema#string

Johan Dalén

http://www.w3.org/2001/XMLSchema#string

Sumesh Kachroo

http://www.w3.org/2001/XMLSchema#string

P2860

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug

Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany

Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis.

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.

Effect of personal and cultural beliefs on medication adherence in the elderly.

P2888

s00296-017-3825-z

P304

2049-2058

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00296-017-3825-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christopher M. Black

P577

2017-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28975392

http://www.w3.org/2001/XMLSchema#string